- New agreement adds two Telix investigational PET imaging radiotracers to GE Healthcare’s immuno-diagnostic portfolio, to enable patient selection and monitoring in immunotherapy trials
- Telix tracers evaluate levels of carbonic anhydrase IX and lactate in tumours to inform and improve therapy selection
- GE Healthcare’s Pharmaceutical Diagnostics business is an established global supplier of PET imaging tracers to the global clinical research market
Melbourne (Australia) – 17 October 2022.